Catalyst Pharmaceuticals (CPRX)

Executive Summary

Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company specializing in rare neuromuscular and neurological diseases. With a proven track record in orphan drug development and commercialization, the company has built a profitable business through its lead product, Firdapse (amifampridine phosphate), approved for Lambert-Eaton myasthenic syndrome (LEMS). Catalyst’s patient-centric approach and regulatory expertise position it well for sustained growth. The company is expanding its pipeline into additional indications such as congenital myasthenic syndrome (CMS) and spinal muscular atrophy (SMA), leveraging its specialized commercial platform. With strong revenue from Firdapse and a disciplined cost structure, Catalyst remains financially robust. Upcoming catalysts include potential label expansions, regulatory decisions, and pipeline progress, which could drive further value.

Upcoming Catalysts (preview)

• H2 2026FDA decision on supplemental NDA for Firdapse in congenital myasthenic syndrome (CMS)60% success
• 2026Phase 2 data readout for amifampridine phosphate in spinal muscular atrophy (SMA)50% success
• TBDPotential acquisition or in-licensing of a new late-stage neurology asset30% success